000 02886cam a2200349 a 4500
003 EG-GiCUC
005 20250223032408.0
008 190928s2019 ua dh f m 000 0 eng d
040 _aEG-GiCUC
_beng
_cEG-GiCUC
041 0 _aeng
049 _aDeposite
097 _aM.Sc
099 _aCai01.11.28.M.Sc.2019.He.A
100 0 _aHebatullah Mohammed Zaki Eldin Hefny
245 1 0 _aAutoimmune hepatitis in children characteristics and treatment outcome /
_cHebatullah Mohammed Zaki Eldin Hefny ; Supervised Hanaa Mostafa Elkaraksy , Engy Adel Mogahed , Hala Mohsen Abdulsalam Abdullatif
246 1 5 _aالتهاب الكبد المناعي الذاتي عند الأطفال خصائصه ونتائجه العلاجيه
260 _aCairo :
_bHebatullah Mohammed Zaki Eldin Hefny ,
_c2019
300 _a106 P. :
_bcharts , facsimiles ;
_c25cm
502 _aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Pediatrics
520 _aBackground and aim: Autoimmune hepatitis (AIH) is a progressive inflammatory liver disorder of unknown etiology and different clinical presentations. The aim of our study is to determine the clinical, biochemical and histopathological characteristics, types of immunosuppressive therapy used and treatment outcomes of children with AIH. Methods: This observational study included all children presented to the Pediatric Hepatology Unit at Cairo University Pediatric Hospital, Egypt from January 2009 to December 2016 with established diagnosis of AIH. All data were retrieved from the patients' files. Results: Thirty-four AIH children were included. The mean ± SD age at disease onset was 7.2 ± 2.8 years. Sixty-one percent presented with a picture of chronic liver disease, meanwhile 27.8% presented with acute hepatitic illness and 11.1% with acute liver failure. Jaundice was the main presenting symptom in 79.4%. Transaminases were elevated in all patients on initial presentation. Synthetic dysfunction was present in half the patients.Twenty-six patients (76.4%) were type 1 AIH, while seven (20.5%) were type 2 AIH and one patient (2.9%) was autoantibody negative AIH. Liver biopsy findings included distorted hepatic architecture in 83.3% of the patients and piecemeal necrosis in 79%. The initial treatment was oral prednisolone in all patients. Azathioprine was added to prednisolone in the treatment of 88.2% of the patients. Biochemical remission was achieved in 79.8%
530 _aIssued also as CD
653 4 _aAIH
653 4 _aAutoimmune hepatitis
653 4 _aChronic liver disease
700 0 _aEngy Adel Mogahed ,
_eSupervisor
700 0 _aHala Mohsen Abdulsalam Abdullatif ,
_eSupervisor
700 0 _aHanaa Mostafa Elkaraksy ,
_eSupervisor
856 _uhttp://172.23.153.220/th.pdf
905 _aNazla
_eRevisor
905 _aShimaa
_eCataloger
942 _2ddc
_cTH
999 _c74209
_d74209